ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Recent insider buying

<< Previous

Bullboard Posts

Next >>

Comment by retiredcopon Dec 13, 2022 4:30pm

172 Views

Post# 35169475

RE:Recent insider buying

Date	Transaction Date	Insider Name	Ownership Type	Securities	Nature of transaction	Volume or Value	Price
Dec 13/22	Dec 12/22	Williams, Eugene Warren	Direct Ownership	Common Shares	10 - Acquisition in the public market	1,000	$5.08 USD
Dec 13/22	Dec 9/22	Kirwin, Patrick D.	Indirect Ownership	Common Shares	10 - Acquisition in the public market	1,000	$6.80
Dec 10/22	Dec 7/22	Williams, Eugene Warren	Direct Ownership	Common Shares	10 - Acquisition in the public market	1,000	$5.49 USD
Dec 10/22	Dec 6/22	Farfel, Gail	Direct Ownership	Common Shares	10 - Acquisition in the public market	1,000	$5.70 USD
Dec 7/22	Dec 2/22	Williams, Eugene Warren	Direct Ownership	Common Shares	10 - Acquisition in the public market	1,000	$5.98 US